EXTON, Pa., May 9, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody, director of investor relations, will present at the 2013 Bank of America Merrill Lynch Healthcare Conference at 11:20 AM PT (2:20 PM ET) on Tuesday, May 14, 2013. The conference is being held at the Encore at the Wynn Hotel in Las Vegas, NV.
ViroPharma also announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 38th Annual Healthcare Conference at 9:20 AM ET on Wednesday, May 29, 2013. The conference is being held at the Westin Boston Waterfront Hotel.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated